Literature DB >> 20049508

Successful treatment of choroidal neovascular membrane in retinitis pigmentosa with intravitreal bevacizumab.

Archana Malik1, Sunandan Sood, Subina Narang.   

Abstract

We report a rare association of choroidal neovascularization (CNV) with retinitis pigmentosa and note its resolution by intravitreal injection of the anti-vascular endothelial growth factor (VEGF), bevacizumab. A classic choroidal neovascular membrane was seen in the right eye (RE) of a patient with sector retinitis pigmentosa. Bevacizumab 1.25 mg in 0.05 ml was injected intravitreally. The choroidal neovascular membrane was seen to regress following this single intravitreal bevacizumab injection with formation of a scar. CNV has very rarely been seen in association with retinitis pigmentosa. Anti-VEGF drugs have been shown to have a beneficial role in CNV with other causes; in this case their effectiveness in CNV associated with retinal dystrophies, for example retinitis pigmentosa, has been demonstrated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20049508     DOI: 10.1007/s10792-009-9337-4

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  10 in total

1.  [Two cases of retinitis pigmentosa associated with choroidal neovascularization].

Authors:  Ryo Iwakiri; Satoshi Okinami; Akira Hirata
Journal:  Nippon Ganka Gakkai Zasshi       Date:  2007-08

2.  Interferon alpha 2a for treatment of age-related macular degeneration.

Authors:  W E Fung
Journal:  Am J Ophthalmol       Date:  1991-09-15       Impact factor: 5.258

3.  Hereditary retinal dystrophies and choroidal neovascularization.

Authors:  F Marano; A F Deutman; A Leys; A L Aandekerk
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2000-09       Impact factor: 3.117

4.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1999-10

5.  Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Authors:  Robert L Avery; Dante J Pieramici; Melvin D Rabena; Alessandro A Castellarin; Ma'an A Nasir; Matthew J Giust
Journal:  Ophthalmology       Date:  2006-02-03       Impact factor: 12.079

6.  Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration.

Authors:  E Reichel; A M Berrocal; M Ip; A J Kroll; V Desai; J S Duker; C A Puliafito
Journal:  Ophthalmology       Date:  1999-10       Impact factor: 12.079

7.  Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.

Authors:  Wai-Man Chan; Timothy Y Y Lai; David T L Liu; Dennis S C Lam
Journal:  Am J Ophthalmol       Date:  2007-04-24       Impact factor: 5.258

8.  Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.

Authors:  Wai-Man Chan; Timothy Y Y Lai; David T L Liu; Dennis S C Lam
Journal:  Ophthalmology       Date:  2007-06-28       Impact factor: 12.079

9.  Choroidal neovascularisation secondary to Best's disease in a 13-year-old boy treated by intravitreal bevacizumab.

Authors:  Jörg Leu; Norbert F Schrage; Robert F Degenring
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-06-29       Impact factor: 3.117

10.  Radiation therapy for subfoveal choroidal neovascular membranes in age-related macular degeneration. A pilot study.

Authors:  G J Bergink; A F Deutman; J F van den Broek; W A van Daal; R W van der Maazen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-10       Impact factor: 3.117

  10 in total
  9 in total

1.  Transfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheep.

Authors:  Tugba Cakmak Argun; Ozlem Yalcin Tok; Levent Tok; Gulsen Yilmaz; Fatma Meric Yilmaz; Alime Gunes; Mehmet Argun; Osman Butuner
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

2.  NGF/anti-VEGF combined exposure protects RCS retinal cells and photoreceptors that underwent a local worsening of inflammation.

Authors:  Maria Luisa Rocco; Bijorn Omar Balzamino; Graziana Esposito; Carla Petrella; Luigi Aloe; Alessandra Micera
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-12-24       Impact factor: 3.117

Review 3.  Retinitis pigmentosa-associated cystoid macular oedema: pathogenesis and avenues of intervention.

Authors:  S Strong; G Liew; M Michaelides
Journal:  Br J Ophthalmol       Date:  2016-12-02       Impact factor: 4.638

4.  Long-term efficacy and safety of anti-VEGF therapy in retinitis pigmentosa: a case report.

Authors:  Manabu Miyata; Akio Oishi; Maho Oishi; Tomoko Hasegawa; Hanako Ohashi Ikeda; Akitaka Tsujikawa
Journal:  BMC Ophthalmol       Date:  2018-09-14       Impact factor: 2.209

5.  Bilateral Retinal Angiomatous Proliferation in a Variant of Retinitis Pigmentosa.

Authors:  G Aloe; C M De Sanctis; C Strafella; R Cascella; F Missiroli; M Cesareo; E Giardina; F Ricci
Journal:  Case Rep Ophthalmol Med       Date:  2019-07-31

6.  Polypoidal choroidal vasculopathy in a case of retinitis pigmentosa, successfully treated with intravitreal aflibercept.

Authors:  Nana Takahashi; Hiroshi Kunikata; Masayuki Yasuda; Takehiro Hariya; Koji M Nishiguchi; Toru Nakazawa
Journal:  Am J Ophthalmol Case Rep       Date:  2021-05-24

7.  Polypoidal choroidal vasculopathy in a case with retinitis pigmentosa.

Authors:  Tomoka Ishida; Muka Moriyama; Kei Morohoshi; Yuu Furuse; Taiko Fukuda; Kyoko Ohno-Matsui
Journal:  Int Ophthalmol       Date:  2012-11-07       Impact factor: 2.031

8.  Relapse of choroidal neovascularization in Bietti's crystalline retinopathy following anti-vascular endothelial growth factor therapy: A case report.

Authors:  Rui Hua; Kang Chen; Yuedong Hu; Xinling Wang; Lei Chen
Journal:  Exp Ther Med       Date:  2015-09-01       Impact factor: 2.447

9.  Type 3 Neovascularization Associated with Retinitis Pigmentosa.

Authors:  Jihene Sayadi; Alexandra Miere; Eric H Souied; Salomon Y Cohen
Journal:  Case Rep Ophthalmol       Date:  2017-04-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.